Latest Releases
U.S. Senator Tina Smith Joins Elizabeth Warren, Banking Committee Democrats in Pressing SEC Chair to Require Disclosure of Corporate Lobbying Expenditures
Washington, D.C. — Today, U.S. Senators Tina Smith (D – Minn.), Sherrod Brown (D-Ohio.), Jon Tester (D-Mont.) and John Fetterman (D-Pa.) signed onto a letter led by Senator Elizabeth Warren (D – Mass.) urging Gary Gensler, Chair of the U.S. Securities and Exchange Commission (SEC), to create new rules requiring public companies to disclose their spending on lobbying efforts. Public companies are not currently required to report information on the details of their lobbying to the SEC even as corporate lobbying expenditures reach record highs. “In 2022, total federal lobbying expenditures reached $4.1 billion – the highest since 2010. Amazon and Meta spent almost $20 million each to influence decision-making in Congress and across government agencies, while the U.S. Chamber of Commerce – which counts companies like JPMorgan Chase, Alphabet, and Chevron among its members – spent $79.4 million,” wrote the senators. “While these figures are staggering, they provide little insight into the interests that companies spend millions each year to advance. This lack of transparency erodes the ability of everyday investors to make informed decisions about where to invest their money – and where their money goes once they have invested.” Specifically, the senators are requesting that such rules require disclosure of lobbying strategy, the total amount of direct or indirect contributions to registered state and federal lobbyists and any material risks related to or arising from lobbying strategies and expenditures. The senators requested the SEC provide them with details on their plans to develop and issue such rules no later than
U.S. Senators Tina Smith, Tom Cotton Reintroduce Bipartisan Legislation to Boost U.S. Pharmaceutical Manufacturing
WASHINGTON, D.C. — Today, Senators Tina Smith (D-MN) and Tom Cotton (R-AR) reintroduced bipartisan legislation to reduce dependence on foreign pharmaceutical manufacturing and boost production in the U.S. The pandemic exposed our nation’s dependence on other countries for essential prescription drugs. Seventy-seven percent of key pharmaceutical ingredients come from overseas, including from China, threatening the security of the supply chain and leading to shortages of essential prescription drugs. The American Made Pharmaceuticals Act would reduce our dependence on foreign countries for pharmaceuticals by boosting production here at home. The legislation would create federal incentives to onshore manufacturing of essential medicine, while taking steps to shore up links in the supply chain. “We know that depending on foreign countries for key resources – whether it’s oil or medicine – leaves us vulnerable to global supply chain shocks and shortages,” said Sen. Smith. “This bipartisan legislation would reduce our dependence on foreign pharmaceutical manufacturing and help boost production here at home. I look forward to getting this bill across the finish line so we can relieve prescription drug shortages and build more resilient supply chains.” “The Chinese Communist Party threatened to cut off America’s access to vital drugs during the pandemic,” said Sen. Cotton. “It’s time to bolster onshore manufacturing of pharmaceuticals to ensure Americans never have to rely on China for lifesaving medicine.” “Amneal applauds Senators Smith and Cotton on their targeted approach to increase pharmaceutical manufacturing here in the United States,” said Chirag Patel, President & Co-CEO of Amneal Pharmaceuticals. “Ensuring that
Sen. Tina Smith’s Statement on Commerce Dept. Recommendation for Steep New Tariffs on Foreign Steel
Today, U.S. Senator Tina Smith released the following statement on an announcement that the Department of Commerce will recommend heavy new tariffs on foreign steel imports. “One of my first stops as Senator was in Eveleth, home to the U.S. Hockey Hall of Fame, as well as many of the hardest-working men and women in the country,” said Sen. Smith. “When I was there, I talked with local steelworkers about the biggest challenges facing Northern Minnesota. They told me their jobs are at risk if we don’t continue to crack down on steel dumping from countries like China. Since then, I pressed
Sen. Tina Smith Named to Bipartisan Select Committee to Solve Pensions Crisis Facing 22,000 Minnesotans
Sen. Tina Smith was appointed to a newly formed bipartisan panel tasked with finding solutions to a financial crisis that’s threatening the hard-earned pensions of 22,000 retired Minnesotans. The Joint Select Committee on Solvency of Multiemployer Pension Plans, established as part of the bipartisan budget agreement reached earlier this month, will provide recommendations and legislative language to significantly improve the solvency of multiemployer pension plans and the Pension Benefit Guaranty Corporation. Without reforms, as many as 100 pension plans across the country—including the troubled Central States Pension Fund, which covers those 22,000 Minnesotans—are on track to become insolvent. “There are
Sen. Tina Smith’s First Bill Would Address Unscrupulous Big Pharma Tactic That Prevents Minnesotans from Accessing Affordable Rx Drugs
U.S. Senator Tina Smith’s first standalone piece of legislation—the Expanding Access to Low Cost Generic Drugs Act—takes aim at a big pharma tactic that keeps affordable generic drugs out of the hands of Minnesota families and seniors. Sen. Smith’s bill, which she introduced today and is similar to a policy endorsed by the Trump Administration, gets at the heart of a major concern facing Minnesota families and seniors right now: prescription drug prices. We’re at the point now where around 25 percent of Americans who take prescription drugs report difficulty affording them. And while generic drugs are often a much less
Sen. Tina Smith Questions Five Big Pharma CEOs on Use of Corporate Tax Savings
Today, U.S. Senator Tina Smith questioned a group of major pharmaceutical executives on how they are using billions of their corporate tax cut dollars, expressing concern that the companies may be using the funds to enrich investors through stock “buybacks” and shareholder payouts instead of prioritizing lower prescription drug prices. The Tax Cuts and Jobs Act, signed into law in December, reduced the corporate income tax rate by over 40 percent, providing these companies with a large windfall of corporate tax savings that could be used to bring down costs for consumers or invest in new research and development. However,
English